Abpro is one company that is vying for the lead in this race. It has initiated its Phase 2/3 study of ABP300, making it the most advanced COVID antibody developer behind Regeneron and Eli Lilly.
According to preclinical data the company recently published in Nature Communications, ABP300 binds to various strains of COVID variants and may be effective even in people who are infected with the UK or South African variant that has evaded vaccines. With peer reviewed validation, and Phase 1 data showing the drug is safe in healthy people, the company has initiated both a Phase 2/3 study in up to 2,000 patients worldwide who have mild or moderate COVID-19, as well as a program studying ABP300's ability to treat the South African variant specifically.
